Characteristics of Patients With Asthma and History of Coexisting Allergic Rhinitis Initiating Dupilumab in Real-World Clinical Practice: The Rapid Registry Study

Speaker(s)

Peters AT1, Côté A2, Muñoz X3, Lugogo NL4, Price D5, Mosnaim GS6, Xia C7, Gómez LDP8, Kwah J7
1Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 2Quebec Heart and Lung Institute – Laval University, Quebec City, QC, Canada, 3Vall d’Hebron University Hospital, Barcelona, Barcelona, Spain, 4University of Michigan, Ann Arbor, MI, USA, 5Observational and Pragmatic Research Institute, Singapore, Singapore, 6Endeavor Health, Evanston, IL, USA, 7Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, 8Sanofi, Madrid, Madrid, Spain

Presentation Documents

OBJECTIVES: Many patients with asthma present with coexisting type 2 inflammatory diseases such as allergic rhinitis (AR). The RAPID (NCT04287621) global registry enrolled patients with asthma initiating dupilumab in real-world clinical practice. This analysis assessed AR prevalence together with baseline (pre-dupilumab) data in patients who had been enrolled in RAPID for one year.

METHODS: RAPID enrolled patients aged ≥12 years initiating dupilumab for asthma (primary indication) according to country-specific prescribing information. Analyses included baseline characteristics and patient-reported outcomes in patients with or without coexisting AR.

RESULTS: Of 205 patients included in this analysis, 167 (81%) reported a history of AR. In patients with vs without a history of AR, 116/167 (70%) vs 18/38 (47%) were female. Mean (SD) age was 48.2 (17.5) vs 58.4 (14.4) years; body mass index (BMI) was 30.4 (8.1) vs 30.7 (7.1) kg/m2; time since asthma diagnosis was 22.0 (18.6) vs 16.1 (13.7) years; and duration of AR was 12.5 (18.9) years. Mean (SD) percent predicted pre-bronchodilator forced expiratory volume in 1 second (ppFEV1) was 71.1 (19.8)% vs 67.4 (21.9)%. Median (Q1–Q3) eosinophil levels were 330.0 (210.0–695.0) vs 300.0 (90.0–700.0) cells/µL; fractional exhaled nitric oxide (FeNO) was 35.0 (16.0–62.0) vs 33.5 (19.0–49.0) ppb, and baseline total IgE was 226.5 (70.5–791.5) vs 132.0 (43.0–538.0) kU/L. In patients with a history of AR, mean (SD) Allergic Rhinitis Visual Analog (AR-VAS) score was 47.8 (29.3) and Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ(S)+12] score was 2.2 (1.3).

CONCLUSIONS: Over 80% of patients with asthma initiating treatment with dupilumab in real-world clinical practice reported a history of coexisting AR. These patients were predominantly female and younger, with a longer duration of asthma, had increased disease burden, and reduced quality of life compared with those without a history of coexisting AR.

Code

RWD21

Topic

Patient-Centered Research, Study Approaches

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes, Prospective Observational Studies

Disease

Biologics & Biosimilars, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)